dsco Discovery Laboratories Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : dsco Discovery Laboratories

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: gumbydamnit who wrote (1)	3/15/1999 10:42:00 PM
From: FFNEODOC	of 318

Post from A Neonatologist; We've been using Surfactants to treat Respiratory Distress Syndrome for years. Most common are of calf lung extract(Survanta & InfraSurf). Surfaxin (DSCO's product) has a few potential marketing advantages. #1, it's purely synthetic with decreased risk of allergic reaction & cheaper to produce. #2, They have the "Use Patent" for treatment of Meconium Aspiration Syndrome which is currently undergoing clinical trials. (On the FDA fast track entering phase 2-3) This means that even if the other Surfactants work to treat MAS, the labeled use of them for this indication would constitute patent infringement. Will be interesting to follow.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next